Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsPayablesReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CervoMed (CRVO) Other Accumulated Expenses (2022 - 2025)

CervoMed (CRVO) has disclosed Other Accumulated Expenses for 8 consecutive years, with $2.1 million as the latest value for Q1 2025.

  • Quarterly Other Accumulated Expenses rose 47.81% to $2.1 million in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $2.1 million through Mar 2025, up 47.81% year-over-year, with the annual reading at $2.4 million for FY2024, 22.48% up from the prior year.
  • Other Accumulated Expenses hit $2.1 million in Q1 2025 for CervoMed, down from $2.4 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $2.4 million in Q4 2024 to a low of $532550.0 in Q2 2023.
  • Historically, Other Accumulated Expenses has averaged $1.5 million across 4 years, with a median of $1.5 million in 2022.
  • Biggest YoY gain for Other Accumulated Expenses was 200.08% in 2023; the steepest drop was 68.09% in 2023.
  • Year by year, Other Accumulated Expenses stood at $644252.0 in 2022, then skyrocketed by 200.08% to $1.9 million in 2023, then increased by 22.48% to $2.4 million in 2024, then decreased by 12.05% to $2.1 million in 2025.
  • Business Quant data shows Other Accumulated Expenses for CRVO at $2.1 million in Q1 2025, $2.4 million in Q4 2024, and $2.2 million in Q3 2024.